Antisense News and Research

RSS

Antisense is the non-coding strand in double-stranded DNA. The antisense strand serves as the template for mRNA synthesis.

QurAlis gears up for clinical development of therapeutic candidate, QRL-101

(BUSINESS WIRE)--QurAlis Corporation, a biotech company developing breakthrough precision medicines for ALS and other genetically validated neurodegenerative diseases, today announced the publication of an article in Cell Reports.

9 Jun 2021

UVA researchers discover potential treatment approaches for muscle loss in myotonic dystrophy type 1

University of Virginia School of Medicine researchers have identified new insights and potential treatment approaches for muscle loss in myotonic dystrophy type 1 (DM1), the most common form of muscular dystrophy.

7 Jun 2021

Researchers identify new approach to clear toxic Huntingtin protein

Researchers world-wide are focused on clearing the toxic mutant Huntingtin protein that leads to neuronal cell death and systemic dysfunction in Huntington's disease (HD), a devastating, incurable, progressive neurodegenerative genetic disorder.

2 Jun 2021

Synthetic microRNA can serve as a novel therapeutic agent for treating human cancer

Oncotarget published "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology" which reported that the authors comprehensively investigated miRNA-193a-3p's mode of action in a panel of human cancer cell lines, with a variety of genetic backgrounds, using 1B3, a synthetic microRNA mimic

2 Jun 2021

Intranasal COVID-19 therapeutic shows promise in preclinical trials

Researchers from the US and Denmark recently described a novel therapeutic option that targets the SARS-CoV-2 ribonucleic acid (RNA) using locked nucleic acid antisense oligonucleotides (LNA ASOs). They identified an LNA ASO that binds to the 5’ leader sequence of SARS-CoV-2 ORF1a/b. This disrupts a highly conserved stem-loop structure with nanomolar efficacy and inhibits viral replication in host cells.

20 May 2021

Study may lead to new treatments for a wide range of neurological conditions

New research published today sheds important light on how the production of a key protein in the brain is controlled, which could pave the way for new treatments for a wide range of neurological conditions.

19 May 2021

Brain-targeting drug delivery with nano-scaled apoptotic bodies

Scientists from Nanjing University and University of Macau have discovered nano-scaled apoptotic bodies (ABs) as a new brain-targeting drug carrier, bringing new promise for the Parkinson's Disease as well as other brain diseases.

7 May 2021

New efforts to improve the efficacy of nucleotide-based drugs against prostate cancer, bone metastasis

Published in the Advanced Functional Materials, University of Minnesota researcher Hongbo Pang led a cross-institutional study on improving the efficacy of nucleotide-based drugs against prostate cancer and bone metastasis.

21 Apr 2021

Single injection of RNA therapy improves vision in patient with genetic form of childhood blindness

A Penn Medicine patient with a genetic form of childhood blindness gained vision, which lasted more than a year, after receiving a single injection of an experimental RNA therapy into the eye.

1 Apr 2021

The role of nanotechnology in the fight against COVID-19

Appearing in the journal Nanomedicine, the review summarized all the exciting advances made using diverse nanomaterials (polymeric, inorganic self-assembling materials and peptide-based) towards COVID-19 prevention, diagnosis and therapy.

15 Mar 2021

NTU scientists design new compound that could help reduce overactive immune response

When the body detects a pathogen, such as bacteria or viruses, it mounts an immune system response to fight this invader. In some people, the immune system overreacts, resulting in an overactive immune response that causes the body to injure itself, which may prove fatal in some cases.

10 Mar 2021

New compound can reduce overactivation without impairing the body's immunity response

10 Mar 2021

New evidence supports the use of antisense oligonucleotides as feasible therapeutic strategy for MDS

Many cognitive neurodevelopmental disorders are a result of too many or too few copies of certain genes or chromosomes.

5 Mar 2021

Researchers develop a genetic patch to prevent hereditary deafness

They can hear well up to about forty years old, but then suddenly deafness strikes people with DFNA9. The cells of the inner ear can no longer reverse the damage caused by a genetic defect in their DNA.

2 Mar 2021

FDA approval provides targeted treatment option for patients with rare DMD mutation

Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person's genome).

25 Feb 2021

mRNA Therapeutics – Analytical and Bioanalytical Characterization

NewsMed interviews Anette Bak from AstraZeneca about her research on developments in mRNA therapeutics that she will present at Pittcon 2021.

From Pittcon 23 Feb 2021

Researchers explain SARS-CoV-2's replication-transcription complex

The current pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still spreading rapidly throughout the world. A new preprint on the bioRxiv* server describes the structure of an important viral non-structural protein NSP12-16 and its role in SARS-CoV-2 infection.

22 Feb 2021

AACR and MPM award three grants to support groundbreaking cancer research projects

Three grants for research that could transform cancer therapies have been awarded by the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Grants Program, an innovative partnership between the American Association for Cancer Research and the UBS Oncology Impact Fund managed by MPM Capital.

21 Jan 2021

Designer DNA agent reduces myeloma stem cell abundance, lowers disease burden in mice

Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That's in part because cancer stem cells drive the disease -- cells that continually self-renew. If a therapy can't completely destroy these malignant stem cells, the cancer is likely to keep coming back.

20 Jan 2021

Researchers develop ultra-small nanomedicines to target intractable cancers

Ultra-small nanomedicines of approximately 18 nm were fabricated by dynamic ion-pairing between Y-shaped block copolymers and nucleic acid drugs, such as siRNA and antisense drugs.

19 Jan 2021